|
1.
|
|
18 p, 948.8 KB |
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain : A Systematic Review
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Freire, Lourdes Rodríguez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Burgos-Pol, Ramón (Pharmacoeconomics and Outcomes Research Iberia (PORIB)) ;
Gomez, Ismael (Pfizer S.L.U.) ;
Peral, Carmen (Pfizer S.L.U.) ;
Gomez, Susana (Pfizer S.L.U.) ;
Rebollo Laserna, Francisco José (Pfizer S.L.U.) ;
Universitat Autònoma de Barcelona
Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a systematic review of the economic assessments conducted on the use of ETN in the treatment of both PSO and PsA in Spain. [...]
2019 -  10.1007/s13555-019-0301-6
Dermatology and Therapy, Vol. 9 Núm. 3 (january 2019) , p. 479-496
|
|
|
2.
|
|
24 p, 525.4 KB |
Elevating the Standard of Care for Patients with Psoriasis : 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative
/
Koren, Jan (EUROPSO, Polzela, Slovenia) ;
Lambert, Jo (Ghent University) ;
Thomsen, Simon F. (University of Copenhagen) ;
McAteer, Helen (Psoriasis Association) ;
Fabbrocini, Gabriella (University of Naples Federico II) ;
Corazza, Valeria (Italian Psoriatic Association Friends of the Corazza Foundation) ;
Jullien, Denis (Lyon-1 University) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Warren, Richard B. (University of Manchester) ;
de Rie, Menno A. (University of Amsterdam) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Guillevin, Loïc (Université Paris Descartes) ;
Grosser, Marius (German Psoriasis Association) ;
Boehncke, Wolf-Henning (University of Geneva) ;
Universitat Autònoma de Barcelona
Despite advances in treatment options and the management of patients with psoriasis, considerable unmet needs remain. Our objective was to identify ways to elevate the standard of care for patients with psoriasis by combining the perspectives of three important stakeholders: patients, clinicians and payors, and define 'Calls to Action' designed to achieve the identified changes. [...]
2022 - 10.1007/s13555-022-00846-3
Dermatology and Therapy, december 2022, p. 1-24
|
|
|
3.
|
|
11 p, 464.0 KB |
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
/
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Barbarot, Sebastien (Department of Dermatology. Nantes Université. CHU Nantes. INRAE) ;
Grond, Susanne (Eli Lilly and Company) ;
Schuster, Christopher (Eli Lilly and Company) ;
Petto, Helmut (Eli Lilly and Company) ;
Capron, Jean-Philippe (Eli Lilly and Company) ;
Raibouaa, Afaf (Eli Lilly and Company) ;
Werfel, Thomas (Division of Immunodermatology and Allergy Research. Department of Dermatology and Allergy. Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Indirect treatment comparison was used to compare approved doses of baricitinib and dupilumab for treating adult patients with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. [...]
2022 - 10.1007/s13555-022-00734-w
Dermatology and Therapy, Vol. 12 Núm. 6 (june 2022) , p. 1481-1491
|
|
|
4.
|
|
18 p, 951.7 KB |
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis : A Network Meta-Analysis
/
Armstrong, April W (Department of Dermatology. Keck School of Medicine. University of Southern California) ;
Soliman, A.M. (AbbVie. Inc.) ;
Betts, Keith A (Analysis Group. Inc.) ;
Wang, Y. (Analysis Group. Inc.) ;
Gao, Y. (Analysis Group. Inc.) ;
Stakias, V. (AbbVie. Inc.) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Introduction: The long-term benefit-risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized. Methods: Randomized controlled trials (RCTs) of licensed and investigational treatments for moderate-to-severe plaque psoriasis were identified through a systematic literature review through 2 May 2021. [...]
2022 - 10.1007/s13555-021-00647-0
Dermatology and Therapy, Vol. 12 Núm. 1 (january 2022) , p. 167-184
|
|
|
5.
|
|
12 p, 991.4 KB |
Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis : A Post Hoc Analysis of 3 Phase 3 Studies
/
Buhl, Timo (University Medical Center Göttingen) ;
Rosmarin, D. (Tufts Medical Center) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Fernandez-Peñas, P. (The Skin Hospital) ;
Igarashi, A. (NTT Medical Center) ;
Konstantinou, M.P. (Larrey University Hospital) ;
Chen, S. (Tigermed) ;
Lu, N. (IQVIA) ;
Pierce, E. (Eli Lilly and Company) ;
Casillas, Marta (Eli Lilly and Company)
Introduction: Burdensome symptoms of atopic dermatitis include itch and sleep disturbance. This post hoc analysis reports the effect of baricitinib on itch and sleep disturbance during the first week of treatment in 3 phase 3 studies. [...]
2021 - 10.1007/s13555-021-00534-8
Dermatology and Therapy, Vol. 11 Núm. 3 (june 2021) , p. 971-982
|
|
|
6.
|
|
14 p, 632.2 KB |
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Bakulev, A.L. (Saratov State Medical University) ;
Kokhan, M.M. (Ural Research Institute of Dermatovenerology and Immunopathology) ;
Samtsov, A.V. (S. M. Kirov Military Medical Academy) ;
Khairutdinov, V.R. (S. M. Kirov Military Medical Academy) ;
Morozova, M.A. (JSC BIOCAD) ;
Zolkin, N.A. (JSC BIOCAD) ;
Kuryshev, I.V. (JSC BIOCAD) ;
Petrov, A.N. (JSC BIOCAD) ;
Artemeva, A.V. (JSC BIOCAD) ;
Zinkina-Orikhan, A.V. (JSC BIOCAD)
Introduction: Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety of two NTK regimens vs. [...]
2021 - 10.1007/s13555-021-00554-4
Dermatology and Therapy, Vol. 11 Núm. 4 (august 2021) , p. 1319-1332
|
|
|
7.
|
|
4 p, 172.8 KB |
A Response to : Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
/
Armstrong, April W. (University of Southern California. Department of Dermatology) ;
Soliman, Ahmed M. (AbbVie, Inc) ;
Betts, Keith A. (Analysis Group, Inc) ;
Wang, Yan (Analysis Group, Inc) ;
Gao, Yawen (Analysis Group, Inc) ;
Stakias, Vassilis (AbbVie, Inc) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-022-00812-z
Dermatology and Therapy, Vol. 12 (october 2022) , p. 2867-2870
|
|
|
8.
|
|
17 p, 1.7 MB |
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years : Pooled Analyses from the reSURFACE Pivotal Studies
/
Thaçi, Diamant (University of Lübeck. Institute and Comprehensive Center for Inflammation Medicine) ;
Gerdes, Sascha (University Medical Center Schleswig-Holstein. Department of Dermatology, Venereology and Allergology, Center for Inflammatory Skin Diseases) ;
Du Jardin, Kristian Gaarn (Almirall R&D, Barcelona, Spain) ;
Perrot, Jean-Luc (University Hospital of St-Etienne. Department of Dermatology) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Tildrakizumab (TIL), a monoclonal antibody that selectively targets interleukin-23p19, has been approved for the treatment of moderate-to-severe plaque psoriasis. According to the European Medicines Agency Summary of Product Characteristics, the recommended dose is 100 mg, but a 200 mg dose can be used in patients with certain characteristics, such as a high disease burden or body weight (BW) ≥ 90 kg. [...]
2022 - 10.1007/s13555-022-00793-z
Dermatology and Therapy, Vol. 12 (september 2022) , p. 2325-2341
|
|
|
9.
|
|
16 p, 1.2 MB |
Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
/
Thaçi, Diamant (University of Luebeck) ;
Strober, Bruce (Yale University) ;
Gordon, Kenneth B. (Medical College of Wisconsin) ;
Foley, Peter (The University of Melbourne) ;
Gooderham, Melinda (Queen's University and Probity Medical Research) ;
Morita, Akimichi (Nagoya City University) ;
Papp, Kim A. (Clinical Research and Probity Medical Research) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Menter, M. Alan (Baylor University Medical Center) ;
Colombo, Matthew J. (Bristol Myers Squibb) ;
Elbez, Yedid (Bristol Myers Squibb) ;
Kisa, Renata M. (Bristol Myers Squibb) ;
Ye, June (Bristol Myers Squibb) ;
Napoli, Andrew A. (Bristol Myers Squibb) ;
Wei, Lan (Bristol Myers Squibb) ;
Banerjee, Subhashis (Bristol Myers Squibb) ;
Merola, Joseph F. (Harvard Medical School) ;
Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ;
Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510
|
|
|
10.
|
|
1 p, 118.3 KB |
Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
/
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Langley, Richard G. (Dalhousie University) ;
Paul, Carle (Paul Sabatier University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ;
van de Kerkhof, Peter (Radboud University Medical Center) ;
Wu, Hsiuan-Lin (Amgen Inc) ;
Richter, Sven (Amgen Inc) ;
Jardon, Shauna (Amgen Inc) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
